 | | | | Related Healthscout Videos | |
|
Page: << Prev | 1 | 2 The findings are published in the March 24 issue of The Lancet.
In an accompanying comment in the journal, Jacqueline French, of the University of Pennsylvania, said physicians who are overwhelmed by the number of available antiepileptic drugs will welcome the results of the SANAD trial.
But, she noted that the SANAD study "was too small to address even the most common serious adverse event related to the drugs that were tested ... therefore, it might be wiser to conclude from SANAD that lamotrigine is the drug of first choice in patients with partial seizures, and valproate for patients with generalized or unclassified seizures in the absence of factors that would lead to an alternative choice."
Text Continues Below
Dr. Steven V. Pacia, director of the Lenox Hill Hospital Comprehensive Epilepsy Center in New York, agreed. Calling the studies well-conceived and a reasonable guideline to physicians, he added that caution should be exercised in applying the findings to all patients.
"We must be careful that these findings do not lead health-care systems and insurance carriers to exclude important medications that they consider 'second-line,' but may be vital for a patient that may not tolerate the 'first-line' medication," Pacia said in a prepared statement.
More information
The Epilepsy Foundation has more about medications for epilepsy.
Page: << Prev | 1 | 2
-- Robert Preidt
|
.gif)
